| Oct 2 |
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
|
| Sep 27 |
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
|
| Sep 23 |
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
|
| Sep 16 |
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
|
| Sep 11 |
DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
|
| Sep 5 |
Insider Sale: COO Kristen Oelschlager Sells Shares of Castle Biosciences Inc (CSTL)
|
| Sep 5 |
Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
|
| Aug 28 |
Castle Biosciences to Participate in Upcoming Investor Conferences
|
| Aug 16 |
Castle Biosciences: Inflection Into Profitability
|
| Aug 7 |
Castle Biosciences Second Quarter 2024 Earnings: Beats Expectations
|
